Over the past forty years the availability of coagulation factor replacement therapy has greatly contributed to the improved care of people with hemophilia. Following the blood-borne viral infections in the late 1970s and early 1980, caused by coagulation factor concentrates manufactured using non-virally inactivated pooled plasma, the need for safer treatment became crucial to the hemophilia community. The introduction of virus inactivated plasma-derived coagulation factors and then of recombinant products has revolutionized the care of these people. These therapeutic weapons have improved their quality of life and that of their families and permitted home treatment, i.e., factor replacement therapy at regular intervals in order to prevent both bleeding and the resultant joint damage (i.e. primary prophylaxis). Accordingly, a near normal lifestyle and life-expectancy have been achieved. The main current problem in hemophilia is the onset of alloantibodies inactivating the infused coagulation factor, even though immune tolerance regimens based on long-term daily injections of large dosages of coagulation factors are able to eradicate inhibitors in approximately two-thirds of affected patients. In addition availability of products that bypass the intrinsic coagulation defects have dramatically improved the management of this complication. The major challenges of current treatment regimens, such the short half life of hemophilia therapeutics with need for frequent intravenous injections, encourage the current efforts to produce coagulation factors with more prolonged bioavailability. Finally, intensive research is devoted to gene transfer therapy, the only way to ultimately obtain cure in hemophilia.

Hemophilia: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Diagnosis and Screening in a concise format. The editors have built Hemophilia: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Hemophilia: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

The book Hemophilia - Recent Advances covers various rapid advances being made in this field. The authors have produced state-of-the art chapters. Over some decades, management of hemophilia has progressed from episode based to prophylaxis. It has moved from plasma and cryoprecipitate to new generations of recombinant coagulation factors. Efforts have been made to cover recent advances in the field. The intricacies of genotype and phenotype of hemophilia are explained. Management with recombinant factors has added to problems like inhibitors, which require more skillful handling. Perioperative management of hemophilia is also explained. Every chapter of this book is peer reviewed and evidence based. The information provided in this book makes the readers well informed and more inquisitive, thereby raising new issues, innovation, and research.

Harwood-Nuss' Clinical Practice of Emergency Medicine presents a clinically focused and evidence-based summary of emergency medicine. Chapters are templated to include the clinical presentation, differential diagnosis, evaluation, management and disposition, with highlighted critical interventions and common pitfalls. Management and disposition are especially critical in the emergency department, and their emphasis is unique to Harwood-Nuss. Often, a diagnosis can not be made, given the constraints of an ED evaluation; thus, effecive management of the patient, with or without a confirmed diagnosis, is key. Also distinct to Harwood-Nuss is the High-Risk Chief Complaints section, which covers the key presentations in the ED: chest pain, abdominal pain, shortness of breath, altered mental status. When patients present in the ED, they don't present with a known diagnosis; this chapter walks the physician through possible differential diagnoses and the evaluation and management of these patients so that they can be stabilized and treated quickly and effectively.

Up-to-date, must-know coverage Bring your understanding of the rapidly evolving world of pharmacological agents and their impact on rehabilitation up to date with the Updated 5th Edition of this groundbreaking reference. An easy-to-understand writing style and easy-to-follow design help you to understand the what, why, and how of this complex subject to ensure the most effective plans of care for your patients.

Make the most effective diagnostic and therapeutic decisions in the least time! A best seller for over 25 years, The5-Minute Clinical Consult 2018 is a practical and useful resource for clinicians in primary care, family medicine, emergency medicine, nursing, and pediatrics. It provides rapid access to guidance on diagnosis, treatment, medications, follow-up, and associated factors for more than 540 diseases and conditions. The5-Minute Clinical Consult 2018 is designed to deliver maximum clinical confidence as efficiently as possible...allowing you to focus your valuable time on giving your patients the best possible care. Find the answers you need quickly thanks to an intuitive, at-a-glance format, with concise, bulleted text; hundreds of diagnostic and therapeutic algorithms; ICD-10 codes, DSM-5 criteria; and much more. Make confident decisions aided by current evidence-based designations in each topic. Written by esteemed internal medicine and family medicine practitioners and published by the leading publisher in medical content, The 5-Minute Clinical Consult 2018, 26th Edition includes a Free Trial to 5MinuteConsult.com.

This text provides comprehensive and timely coverage of the current knowledge of cancer-associated thrombosis, its pathogenesis, clinical features, prevention, and therapy. It specifically addresses the relationship between hemostatic systems and cancer, thus providing a unique and much needed focus. All of the contributors are acknowledged specialists in their fields and have experience conducting large clinical trials in oncology and thrombosis. Their discussions cover all aspects of the topic, from long-term complications to cancer surgery. It will be of interest to general practitioners, internists, oncologists, hematologists, and all physicians involved in the management of cancer patients.